Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 20;4(6):e485.
doi: 10.1097/HS9.0000000000000485. eCollection 2020 Dec.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Heinz Gisslinger  1 , Christoph Klade  2 , Pencho Georgiev  3 , Dorota Krochmalczyk  4 , Liana Gercheva-Kyuchukova  5 , Miklos Egyed  6 , Viktor Rossiev  7 , Petr Dulicek  8 , Arpad Illes  9 , Halyna Pylypenko  10 , Lylia Sivcheva  11 , Jiri Mayer  12 , Vera Yablokova  13 , Kurt Krejcy  2 , Hans C Hasselbalch  14 , Robert Kralovics  15 , Jean-Jacques Kiladjian  16
Affiliations

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Heinz Gisslinger et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Efficacy assessment of ropeginterferon alfa-2b (ropegIFN) vs control in 2 age cohorts: <60 years and ≥60 years. (A) Complete haematologic response (CHR) at 24 months [i], CHR response maintenance (from first occurrence to 24 months assessment) [ii]. (B) CHR and improvement in disease burden response at 24 months [i], CHR and improvement in disease burden response maintenance (from first occurrence to 24 months assessment) [ii]. (C) Molecular response at 24 months (last observation carried forward [LOCF]). (D) JAK2V617F (%) relative change from baseline (LOCF) at 12 months and 24 months in patients < 60 years (i) and ≥60 years (ii). (Ropeginterferon alfa-2b: n = 49 [<60 years], n = 46 [≥60 years]; control: n = 39 [ < 60 years], n = 37 [≥60 years]).
See this image and copyright information in PMC

References

    1. Bose P, Verstovsek S. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019;10:1–13. - PMC - PubMed
    1. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–1069. - PMC - PubMed
    1. Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15:1193–1207. - PubMed
    1. Hasselbalch HC, Holmstrom MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41:5–19. - PMC - PubMed
    1. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8:3. - PMC - PubMed